Iron-chelating therapy and the treatment of thalassemia.
暂无分享,去创建一个
[1] G. Michel,et al. FIRST REPORT OF A CARDIAC TRANSPLANTATION IN A PATIENT WITH THALASSAEMIA MAJOR , 1991, British journal of haematology.
[2] D. Nathan,et al. Treatment of Cooley's anemia [see comments] , 1990 .
[3] K. Ganeshaguru,et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major , 1993, British journal of haematology.
[4] B. Zani,et al. Psychosocial aspects of chronic illness in adolescents with thalassaemia major , 1995 .
[5] H. Burger,et al. Studies on the possible mechanism for deficiency of nonsuppressible insulin-like activity in thalassemia major. , 1981, The Journal of clinical endocrinology and metabolism.
[6] R. Puniyani,et al. Oral iron chelation with L1 , 1990, The Lancet.
[7] B. Glaser,et al. Cross‐sectional and longitudinal study of the pituitary‐thyroid axis in patients with thalassaemia major , 1993, Clinical endocrinology.
[8] R. Peto,et al. Survival and desferrioxamine in thalassaemia major. , 1982, British medical journal.
[9] M. Tong,et al. Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.
[10] P. Bentley,et al. Toxicity of oral iron chelator L1 , 1993, The Lancet.
[11] F. Cerutti,et al. Insulin resistance and hyperinsulinemia in homozygous β-thalassemia☆ , 1995 .
[12] R. Gayer,et al. Long‐term effect of splenectomy on transfusion requirements in thalassemia major , 1989, American journal of hematology.
[13] M. C. Ellis,et al. A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.
[14] M. Kogut,et al. Endocrine Abnormalities in Thalassemia Major: Gertrude Costin, MD; Maurice D. Kogut, MD; Carol B. Hyman, MD; Jorge A. Ortega, MD , 1979 .
[15] R. Abeysinghe,et al. ANIMAL TOXICOLOGY OF IRON CHELATOR L1 , 1989, The Lancet.
[16] N. McIntosh. Endocrinopathy in thalassaemia major. , 1976, Archives of disease in childhood.
[17] S. Sherlock,et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. , 1982, Journal of clinical pathology.
[18] R. Grady,et al. New Orally Effective Iron Chelators , 1990, Annals of the New York Academy of Sciences.
[19] R. Gottschalk,et al. Non‐invasive quantitation of liver iron‐overload by magnetic resonance imaging , 1990, British journal of haematology.
[20] J. Greenwood,et al. Letter: Exploration of the common bileduct. , 1974, Lancet.
[21] M. Pippard,et al. THE MANAGEMENT OF IRON CHELATION THERAPY , 1983, British journal of haematology.
[22] B. Halliwell,et al. 1 Iron toxicity and oxygen radicals , 1989 .
[23] E. Chew,et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.
[24] R. Fischer,et al. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone , 1995, British journal of haematology.
[25] R. Chatterjee,et al. Prospective study of the hypothalamic‐pituitary axis in thalassaemic patients who developed secondary amenorrhoea , 1993, Clinical endocrinology.
[26] D. Weatherall,et al. IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA , 1979, The Lancet.
[27] G. Faa,et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. , 1994, The Journal of pediatrics.
[28] D. Weatherall,et al. Editorial retrospective. Iron loading in thalassemia--five years with the pump. , 1983, The New England journal of medicine.
[29] G. Lupi,et al. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. , 1990, Circulation.
[30] F. Jensen,et al. Non‐invasive assessment of tissue iron overload in the liver by magnetic resonance imaging , 1994, British journal of haematology.
[31] R. Macdonald,et al. Hemochromatosis and hemosiderosis. Study of 211 autopsied cases. , 1960, Archives of internal medicine.
[32] S. R. Mills,et al. Computed Tomographic Analysis of Beta‐Thalassemic Syndromes with Hemochromatosis: Pathologic Findings with Clinical and Laboratory Correlations , 1980, Journal of computer assisted tomography.
[33] Mark L. Bassett,et al. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis , 1986, Hepatology.
[34] R. Puniyani,et al. Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.
[35] A. Hoffbrand,et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. , 1987, British medical journal.
[36] A. Meikle,et al. Hypogonadism in hemochromatosis: reversal with iron depletion. , 1984, Annals of internal medicine.
[37] S. Shurin,et al. Reassessment of the use of desferrioxamine B in iron overload. , 1976, The New England journal of medicine.
[38] A. Cohen,et al. Treatment of Iron Overload in Cooley's Anemia a , 1985, Annals of the New York Academy of Sciences.
[39] M. Becker,et al. PREVENTION OF BONE MALFORMATIONS AND CARDIOMEGALY IN COOLEY'S ANEMIA BY EARLY HYPERTRANSFUSION REGIMEN * , 1969, Annals of the New York Academy of Sciences.
[40] G. Koren,et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia , 1992 .
[41] A. Hoffbrand,et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. , 1987, Journal of clinical pathology.
[42] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[43] G. Lucarelli,et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia , 1995, British journal of haematology.
[44] B. Modell. Advances in the use of iron-chelating agents for the treatment of iron overload. , 1979, Progress in hematology.
[45] J. Heathcote,et al. The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] G. Koren,et al. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. , 1991, International journal of hematology.
[47] D. Weatherall,et al. IRON CHELATION WITH ORAL DESFERRIOXAMINE , 1980, The Lancet.
[48] M. Freedman,et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. , 1990, American journal of diseases of children.
[49] V. De Sanctis,et al. The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients. , 1986, Postgraduate medical journal.
[50] M. A. Engle,et al. Late Cardiac Complications of Chronic, Severe, Refractory Anemia with Hemochromatosis , 1964, Circulation.
[51] S. Stray,et al. Plasma ferritin determination as a diagnostic tool. , 1986, The Western journal of medicine.
[52] M. Freedman,et al. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. , 1990, The New England journal of medicine.
[53] C. Hyman,et al. Combined Subcutaneous and High‐Dose Intravenous Deferoxamine Therapy of Thalassemia a , 1985, Annals of the New York Academy of Sciences.
[54] A. Castriota-Scanderbeg,et al. Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis. , 1991, Haematologica.
[55] W. Roberts,et al. Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.
[56] Y. Rahman,et al. Studies of an oral iron chelator: 1,2 ‐dimethyl‐ 3 ‐hydroxy‐pyrid‐4‐one I. IRON EXCRETION IN RATS: DEVELOPMENT OF A NEW RAPID MICROWAVE METHOD FOR IRON ANALYSIS IN FAECES , 1990, British journal of haematology.
[57] G. Kontoghiorghes. Iron mobilization from ferritin using α-oxohydroxy heteroaromatic chelators , 1986 .
[58] G. Kontoghiorghes. NEW ORALLY ACTIVE IRON CHELATORS , 1985, The Lancet.
[59] K. Ehlers,et al. The Effect of Subcutaneous Deferoxamine on the Cardiac Profile of Thalassemia Major: A Five‐Year Study , 1985, Annals of the New York Academy of Sciences.
[60] D. Caramella,et al. Assessment of Liver Iron Overload in Thalassemic Patients by Mr Imaging , 1992, Acta radiologica.
[61] D. Nathan,et al. New approaches to the transfusion management of thalassemia , 1980 .
[62] S. Aust,et al. Superoxide generation by NADPH-cytochrome P-450 reductase: the effect of iron chelators and the role of superoxide in microsomal lipid peroxidation. , 1984, Archives of biochemistry and biophysics.
[63] A. Tajik,et al. Echocardiographic features of idiopathic hemochromatosis. , 1987, The American journal of cardiology.
[64] J. Bett,et al. Congestive cardiomyopathy and haemochromatosis--rapid progression possibly accelerated by excessive ingestion of ascorbic acid. , 1982, Australian and New Zealand journal of medicine.
[65] E. Wills. Lipid peroxide formation in microsomes. The role of non-haem iron. , 1969, The Biochemical journal.
[66] C. Borgna-Pignatti,et al. VISUAL LOSS IN PATIENT ON HIGH-DOSE SUBCUTANEOUS DESFERRIOXAMINE , 1984, The Lancet.
[67] J. Lloyd-Still,et al. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. , 1988, American journal of diseases of children.
[68] M. Gotsman,et al. Cardiopulmonary assessment in beta-thalassemia major. , 1990, Chest.
[69] G. Lucarelli,et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies , 1995, British journal of haematology.
[70] G. Brittenham. Noninvasive Methods for the Early Detection of Hereditary Hemochromatosis a , 1988, Annals of the New York Academy of Sciences.
[71] R. Vassilopoulou-sellin,et al. Hemoglobin as a Direct Inhibitor of Cartilage Growth In Vitro , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[72] R. O'brien. ASCORBIC ACID ENHANCEMENT OF DESFERRIOXAMINE‐INDUCED URINARY IRON EXCRETION IN THALASSEMIA MAJOR * , 1974, Annals of the New York Academy of Sciences.
[73] J. Wilkinson,et al. Pteroylpolyglutamic acids in the treatment of pernicious anaemia. , 1949, Lancet.
[74] G. Cecchetti,et al. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. , 1991, European heart journal.
[75] G. Koren,et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients , 1990, The Lancet.
[76] A. Hoffbrand,et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. , 1990, Acta haematologica.
[77] A. Aisen,et al. MR Evaluation of Liver Iron Overload , 1988, Journal of computer assisted tomography.
[78] D. Templeton,et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[79] S. Singhal,et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 , 1991, The Lancet.
[80] A. Cerami,et al. The Use of Chang Cells Cultured in Vitro to Evaluate Potential Iron Chelating Drugs , 1976, British journal of haematology.
[81] L. Marcelis,et al. HORSE RESERVOIR FOR BORRELIA BURGDORFERI? , 1987, The Lancet.
[82] C. Peterson,et al. Abnormal glucose tolerance in β-thalassemia major , 1977 .
[83] G. Lucarelli,et al. Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. , 2008, Liver.
[84] M. Savage,et al. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. , 1994, Archives of disease in childhood.
[85] R. Orton,et al. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. , 1985, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[86] G. Koren,et al. Arthropathy in thalassaemia patients receiving deferiprone , 1994, The Lancet.
[87] W. Anderson,et al. Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .
[88] M. Pippard. 4 Desferrioxamine-induced iron excretion in humans , 1989 .
[89] B. Zinman,et al. Factors determining glucose tolerance in patients with thalassemia major. , 1993, The Journal of clinical endocrinology and metabolism.
[90] H. C. Sutton. Efficiency of chelated iron compounds as catalysts for the Haber-Weiss reaction. , 1985, Journal of free radicals in biology & medicine.
[91] R. Dickerhoff. Acute aphasia and loss of vision with desferrioxamine overdose. , 1987, The American journal of pediatric hematology/oncology.
[92] R. L. Benson,et al. Spontaneous Rupture of the Heart: Report of 40 Cases in Portland, Oregon. , 1933, The American journal of pathology.
[93] A. Hoffbrand,et al. Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIES , 1990, British journal of haematology.
[94] P. Giardina,et al. Deferoxamine-induced bone dysplasia in patients with thalassemia major. , 1991, AJR. American journal of roentgenology.
[95] B. Bacon,et al. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. , 1983, The Journal of clinical investigation.
[96] P. Tongtawe,et al. Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function , 1992, British journal of haematology.
[97] Yun-Fai Chris Lau,et al. A cross‐sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong , 1995, Journal of paediatrics and child health.
[98] R. S. Smith. Chelating Agents in the Diagnosis and Treatment of Iron Overload in Thalassemia , 1964, Annals of the New York Academy of Sciences.
[99] Winfred C. Wang,et al. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. , 1986, The Journal of pediatrics.
[100] M. Zurlo,et al. Insulin dependent diabetes in thalassaemia. , 1988, Archives of disease in childhood.
[101] D. L. Johnston,et al. Assessment of tissue iron overload by nuclear magnetic resonance imaging. , 1989, The American journal of medicine.
[102] A. Hoffbrand,et al. SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD , 1976, The Lancet.
[103] M. Simon,et al. Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis. , 1989, Gastroenterology.
[104] J. Graziano,et al. Depressed serum somatomedin activity in β-thalassemia , 1980 .
[105] D. Weatherall,et al. Iron-chelating therapy. , 1988, Critical reviews in clinical laboratory sciences.
[106] Marie Martin,et al. Depletion of excessive liver iron stores with desferrioxamine , 1984, British journal of haematology.
[107] A. Hoffbrand,et al. L1 (1,2‐dimethyl‐3‐hydroxypyrid‐4‐one) for oral iron chelation in patients with beta‐thalassaemia major , 1990, British journal of haematology.
[108] A. Sonnenberg,et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. , 1985, The New England journal of medicine.
[109] M. Skolnick,et al. Hereditary hemochromatosis. Phenotypic expression of the disease. , 1979, The New England journal of medicine.
[110] D. Fitchett,et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. , 1980, Cardiovascular research.
[111] D. Mishell,et al. Gonadotropin insufficiency in patients with thalassemia major. , 1979, The Journal of clinical endocrinology and metabolism.
[112] E. Schwartz,et al. Scurvy and altered iron stores in thalassemia major. , 1981, The New England journal of medicine.
[113] S. Piomelli,et al. Separation of younger red cells with improved survival in vivo: an approach to chronic transfusion therapy. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[114] P. Toutouzas,et al. Myocarditis in β-Thalassemia Major A Cause of Heart Failure , 1995 .
[115] G. Koren,et al. Acute changes in renal function associated with deferoxamine therapy. , 1990 .
[116] J. Wilkinson,et al. Folic acid in the treatment of pernicious anaemia. , 1946, Lancet.
[117] J. Hocquette,et al. No evidence for a defect in growth hormone binding to liver membranes in thalassemia major. , 1989, The Journal of clinical endocrinology and metabolism.
[118] A. Weinstein. Drug-induced systemic lupus erythematosus. , 1980, Progress in clinical immunology.
[119] P. Merkel,et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. , 1988, The New England journal of medicine.
[120] M. Rapicetta,et al. Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. , 1993, Journal of pediatric gastroenterology and nutrition.
[121] S. Colan,et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.
[122] S. De Virgiliis,et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. , 1988, Archives of disease in childhood.
[123] R. Grossman,et al. MR relaxation times and iron content of thalassemic spleens: an in vitro study. , 1988, AJR. American journal of roentgenology.
[124] P. Athias,et al. Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. , 1989, The Journal of laboratory and clinical medicine.
[125] V. Beral,et al. MALIGNANT-MELANOMA AND FLUORESCENT LIGHTING - REPLY , 1972 .
[126] M. Fosburg,et al. A new approach to neocyte transfusion: Preliminary report , 1988, Journal of clinical apheresis.
[127] C. B. Modell,et al. LONG‐TERM DESFERRIOXAMINE THERAPY IN THALASSEMIA , 1974, Annals of the New York Academy of Sciences.
[128] R. Marcus,et al. A prospective trial of young red cells in 48 patients with transfusion‐dependent thalassaemia , 1985, British journal of haematology.
[129] D. Shaw,et al. CORRELATION BETWEEN COMPUTED TOMOGRAPHIC VALUES AND LIVER IRON CONTENT IN THALASSÆMIA MAJOR WITH IRON OVERLOAD , 1979, The Lancet.
[130] M. Kogut,et al. Carbohydrate Metabolism and Pancreatic Islet-cell Function in Thalassemia Major , 1977, Diabetes.
[131] W. Walsh,et al. Early left ventricular dysfunction and chelation therapy in thalassemia major. , 1983, Annals of internal medicine.
[132] T. Slater. Free-radical mechanisms in tissue injury. , 1984, The Biochemical journal.
[133] C. Yeung,et al. Left ventricular function in beta thalassaemia major. , 1989, Archives of disease in childhood.
[134] F. Cucca,et al. Deferoxamine-induced growth retardation in patients with thalassemia major. , 1988, The Journal of pediatrics.
[135] A. Piga,et al. SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.
[136] C. Finch,et al. Regulators of iron balance in humans. , 1994, Blood.
[137] P. Veys,et al. AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIAL , 1989, The Lancet.
[138] M. Scacchi,et al. Treatment with biosynthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion , 1991, Clinical endocrinology.
[139] V. Locatelli,et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. , 1986, The Journal of clinical endocrinology and metabolism.
[140] Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. , 1990 .
[141] C. McLaren,et al. Binding of Serum Ferritin to Concanavalin A: Patients with Hornozygous β Thalassaemia and Transfusional Iron Overload , 1980, British journal of haematology.
[142] R. Steiner,et al. Magnetic resonance imaging in hemosiderosis. , 1985, Diagnostic imaging in clinical medicine.
[143] H. Roeser,et al. Iron overload associated with congenital pyruvate kinase deficiency and high dose ascorbic acid ingestion. , 1984, Australian and New Zealand journal of medicine.
[144] Z. Varghese,et al. Insulin Resistance and Iron Overload , 1983, Annals of clinical biochemistry.
[145] J. Hou,et al. Prognostic Significance of Left Ventricular Diastolic Indexes in β-Thalassemia Major , 1994 .
[146] I. Adamson,et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning , 1992, The Lancet.
[147] M. D. Lond.. Norman Swift Plummer. , 1978, Lancet.
[148] I. Wolman,et al. SOME CLINICAL FEATURES OF COOLEY'S ANEMIA PATIENTS AS RELATED TO TRANSFUSION SCHEDULES , 1969, Annals of the New York Academy of Sciences.
[149] N. Matsaniotis,et al. Growth of Children with Thalassaemia , 1970, Archives of disease in childhood.
[150] A. Nienhuis,et al. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. , 1979, The New England journal of medicine.
[151] R. Girot,et al. Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect. , 1989, The Journal of clinical endocrinology and metabolism.
[152] B. Wonke,et al. Fertility in β thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature , 1995 .
[153] C. Sklar,et al. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. , 1987, American journal of diseases of children.
[154] A. Hoffbrand,et al. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. , 1994, Journal of clinical pathology.
[155] J. Gomori,et al. Hepatic iron overload: quantitative MR imaging. , 1991, Radiology.
[156] M. O'Connell,et al. The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. , 1985, The Biochemical journal.
[157] M. Cazzola,et al. Relationship between transfusion regimen and suppression of erythropoiesis in β‐thalassaemia major , 1995, British journal of haematology.
[158] G. Brittenham. Development of iron-chelating agents for clinical use. , 1992, Blood.
[159] C. Hershko,et al. Heart cells in culture: a model of myocardial iron overload and chelation. , 1985, The Journal of laboratory and clinical medicine.
[160] I. Gough,et al. OPERATIVE STRATEGY FOR PHAEOCHROMOCYTOMAS LOCALISED BY [131I]-m-IODOBENZYLGUANIDINE SCINTIGRAPHY , 1984, The Lancet.
[161] K. Kovacs,et al. Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. , 1978, The American journal of pathology.
[162] G. Lescoat,et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. , 1992, Journal of hepatology.
[163] L. Wielopolski,et al. Noninvasive in-vivo measurement of hepatic and cardiac iron. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[164] A. Nienhuis. Vitamin C and iron. , 1981, The New England journal of medicine.
[165] A. Hoffbrand,et al. Serum non‐transferrin‐bound iron in beta‐thalassaemia major patients treated with desferrioxamine and L1 , 1992, British journal of haematology.
[166] Pippard Mj. Measurement of iron status. , 1989 .
[167] A. Hoffbrand,et al. Deferiprone‐associated myelotoxicity , 1994, European journal of haematology.
[168] A. Cohen,et al. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. , 1989, The Journal of pediatrics.
[169] M. Freedman,et al. Cardiac Disease–free Survival in Patients with Thalassemia Major Treated with Subcutaneous Deferoxamine , 1990 .
[170] A. Hoffbrand,et al. Orally active α‐ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits , 1986, British journal of haematology.
[171] A. Rahi,et al. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. , 1986, The British journal of ophthalmology.
[172] B. Gersh,et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. , 1987, Journal of the American College of Cardiology.
[173] M. Moseley,et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. , 1985, Radiology.
[174] D. Häussinger,et al. Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.
[175] K. Togashi,et al. Anterior and Posterior Lobes of the Pituitary Gland; Assessment by 1.5 T MR Imaging , 1987, Journal of computer assisted tomography.
[176] S. Curry,et al. Acute iron poisoning. , 1994, Emergency medicine clinics of North America.
[177] N. Olivieri,et al. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine , 1992, American journal of hematology.
[178] A. Cohen,et al. Clinical trial of young red cell transfusions. , 1984, The Journal of pediatrics.
[179] A. Hoffbrand. Oral iron chelation. , 1996, Seminars in hematology.
[180] T. Simon,et al. Extended survival of neocytes produced by a new system , 1989, Transfusion.
[181] R. Mark Henkelman,et al. In vivo measurements of NMR relaxation times , 1985, Magnetic resonance in medicine.
[182] C. Hershko,et al. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid, and alpha-tocopherol in iron-loaded rat myocardial cell cultures. , 1987, The Journal of laboratory and clinical medicine.
[183] P. Rahko,et al. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. , 1986, Journal of the American College of Cardiology.
[184] G. Brittenham,et al. The effect of erythroid hyperplasia on iron balance. , 1988, Blood.
[185] S. Goldberg,et al. Preclinical abnormal segmental cardiac manifestations of thalassemia major in children on transfusion-chelation therapy: echographic alterations of left ventricular posterior wall contraction and relaxation patterns. , 1982, American heart journal.
[186] F. Blei,et al. Chelation therapy and cardiac status in older patients with thalassemia major. , 1990, The American journal of pediatric hematology/oncology.
[187] G. Kontoghiorghes. The study of iron mobilisation from transferrin using α-ketohydroxy heteroaromatic chelators , 1986 .
[188] K. Ehlers,et al. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. , 1991, The Journal of pediatrics.
[189] M. Failla,et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. , 1992, Journal of hepatology.
[190] R. Bannerman,et al. Effect of Desferrioxamine and D.T.P.A. in Iron Overload , 1962, British medical journal.
[191] G. Brittenham,et al. Assessment of bone marrow and body iron stores: old techniques and new technologies. , 1981, Seminars in hematology.
[192] R. Dluhy,et al. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. , 1985, Archives of internal medicine.
[193] G. Arden,et al. OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.
[194] L. Luzzatto,et al. HIGH‐DOSE DESFERRIOXAMINE AS A CAUSE OF GROWTH FAILURE IN THALASSEMIC PATIENTS , 1988, European journal of haematology.
[195] A. Jacobs,et al. Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects , 1979, British journal of haematology.
[196] M. Golub,et al. Studies of marginal zinc deprivation in rhesus monkeys. V. Fetal and infant skeletal effects. , 1984, The American journal of clinical nutrition.
[197] S. Rassu,et al. Endocrine functioning in multitransfused prepubertal patients with homozygous beta-thalassemia. , 1984, The Journal of clinical endocrinology and metabolism.
[198] Z. Hochberg,et al. Neurosecretory Dysfunction of Growth Hormone Secretion in Thalassemia Major , 1990, Acta paediatrica Scandinavica.
[199] Smith Rs. Iron Excretion in Thalassaemia Major After Administration of Chelating Agents , 1962 .
[200] G. Kontoghiorghes. Design, Properties, and Effective Use of the Oral Chelator L1 and Other , 1990, Annals of the New York Academy of Sciences.
[201] W. Bezwoda,et al. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. , 1986, Scandinavian journal of clinical and laboratory investigation.
[202] M. Hilgartner,et al. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance. , 1981, The Journal of pediatrics.
[203] D. Weatherall,et al. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias. , 1978, Clinical science and molecular medicine.
[204] E. Schwartz,et al. Response to long-term deferoxamine therapy in thalassemia. , 1981, The Journal of pediatrics.
[205] K. Bridges,et al. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. , 1986, The Journal of biological chemistry.
[206] B. Halliwell,et al. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. , 1985, Clinical science.
[207] E. Kohner,et al. BROMOCRIPTINE AND SERUM-GROWTHHORMONE LEVELS IN DIABETES MELLITUS , 1975, The Lancet.
[208] J. Eaton,et al. Acute iron poisoning. Rescue with macromolecular chelators. , 1989, The Journal of clinical investigation.
[209] G. Masera,et al. Growth and sexual maturation in thalassemia major. , 1985, The Journal of pediatrics.
[210] D. Jackson,et al. Hormonal changes in thalassaemia major. , 1976, Archives of disease in childhood.
[211] A. Nienhuis,et al. Selective isolation of young erythrocytes for transfusion support of thalassemia major patients. , 1981, Blood.
[212] C. McLaren,et al. Uniformity of liver density and nonheme (storage) iron distribution. , 1987, Archives of pathology & laboratory medicine.
[213] M. Pippard,et al. Ferrioxamine excretion in iron-loaded man. , 1982, Blood.
[214] A. Hoffbrand,et al. EFFECT OF DOSE, TIME, AND ASCORBATE ON IRON EXCRETION AFTER SUBCUTANEOUS DESFERRIOXAMINE , 1977, The Lancet.
[215] G. Brittenham. Pyridoxal Isonicotinoyl Hydrazone , 1990 .
[216] S. Singhal,et al. DEATHS IN PATIENTS RECEIVING ORAL IRON CHELATOR L1 , 1993, British journal of haematology.
[217] H. B. Neustein,et al. Ferritin in Human Liver Cells of Homozygous Beta‐Thalassaemia: Ultrastructural Observations , 1977, British journal of haematology.
[218] A. Hoffbrand,et al. Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators , 1995, British journal of haematology.
[219] B. Bagni,et al. Effect of different treatment regimes on linear growth and final height in β‐thalassaemia major , 1994, Clinical endocrinology.
[220] H. Keberle. The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.
[221] A. Megibow,et al. CT in B-thalassemia: iron deposition in the liver, spleen, and lymph nodes. , 1981, AJR. American journal of roentgenology.
[222] E. Kwan,et al. Growth hormone treatment of short Chinese children with β‐thalassaemia major without GH deficiency , 1995, Clinical endocrinology.
[223] M. Freedman,et al. Growth failure and bony changes induced by deferoxamine. , 1992, The American journal of pediatric hematology/oncology.
[224] A. Hoffbrand,et al. 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOAD , 1987, The Lancet.
[225] R M Henkelman,et al. Transverse relaxation rate enhancement caused by magnetic particulates. , 1989, Magnetic resonance imaging.
[226] S. Underwood,et al. DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJOR , 1984, The Lancet.
[227] J. Lunec,et al. Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage? , 1989, The British journal of ophthalmology.
[228] F. Jensen,et al. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non‐thalassaemic patients , 1995, British journal of haematology.
[229] C. McLaren,et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major , 1993, American journal of hematology.
[230] D. Bowden,et al. Short stature in homozygous β‐thalassaemia is due to disproportionate truncal shortening , 1995, Clinical endocrinology.
[231] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[232] G. Koren,et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.
[233] M. Andreani,et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. , 1993, The New England journal of medicine.
[234] H. Burger,et al. Lack of response of nonsuppressible insulin-like activity to short term administration of human growth hormone in thalassemia major. , 1981, The Journal of clinical endocrinology and metabolism.
[235] M. Freedman,et al. Computed tomography scanning of the liver to determine efficacy of iron chelation therapy in thalassemia major. , 1989, The Journal of pediatrics.
[236] J. O'Brien. DIAGNOSIS OF DEEP-VEIN THROMBOSIS , 1975, The Lancet.
[237] A. Heys,et al. Lipid peroxidation in iron-overloaded spleens. , 1981, Clinical science.
[238] H. Roeser,et al. Serum Ferritin in Ascorbic Acid Deficiency , 1980, British journal of haematology.
[239] H. Bonkovsky,et al. Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. , 1990, Gastroenterology.
[240] G. Brittenham,et al. Experimental liver cirrhosis induced by alcohol and iron. , 1995, The Journal of clinical investigation.
[241] B. Modell. Total management of thalassaemia major. , 1977, Archives of disease in childhood.
[242] A. Markenson,et al. Lens opacities in thalassemia. , 1978, Journal of pediatric ophthalmology and strabismus.
[243] I. Wolman. Transfusion Therapy in Cooley's Anemia: Growth and Health as Related to Long‐Range Hemoglobin Levels. A Progress Report , 1964, Annals of the New York Academy of Sciences.
[244] R. Herst,et al. Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous β‐ thalassemia , 1994, Transfusion.
[245] N. Akar,et al. Effects of zinc supplementation on linear growth in beta‐thalassemia (A new approach) , 1987, American journal of hematology.
[246] D. Todd,et al. Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. , 1989, The Journal of clinical endocrinology and metabolism.
[247] M. Ch,et al. Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. , 1987 .
[248] A. Hoffbrand,et al. IMPROVEMENT IN IRON STATUS AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINE , 1979, The Lancet.
[249] H. Klein,et al. Ex vivo selective isolation of young red blood cells using the IBM-2991 cell washer. , 1983, Blood.
[250] C. Hershko,et al. NON‐TRANSFERRIN PLASMA IRON , 1987, British journal of haematology.
[251] E. Rachmilewitz,et al. Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.
[252] A. Hoffbrand,et al. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. , 1982, Birth defects original article series.
[253] D. Flynn,et al. Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress , 1974, British medical journal.
[254] Stewart Ab,et al. Health centres of today; Finsbury, Peckham. , 1946 .
[255] E. Huehns,et al. 11 The toxic effects of desferrioxamine , 1989 .
[256] J. Tripp,et al. Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.
[257] B. Halliwell,et al. Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.
[258] J. Hazell,et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage , 1989, British journal of haematology.
[259] M. Genel,et al. Carbohydrate homeostasis and pancreatic islet cell funtion in thalassemia. , 1974, Annals of internal medicine.
[260] J W Eaton,et al. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[261] N. Olivieri,et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. , 1996, The Canadian journal of cardiology.
[262] T. Bothwell,et al. Iron Metabolism in Scurvy with Special Reference to Erythropoiesis * , 1964, British journal of haematology.